An anti-inflammatory agent used to treat inflammatory bowel disease.
Salofalk 4g/60ml enemas are used for the treatment of:
inflammation of the large intestine (colon) and rectum (back passage) known by doctors as ulcerative colitis.
It may be used alone or, particularly in the acute phase, with corticosteroids.
Acute attacks of ulcerative colitis (a chronic inflammatory disease of the large bowel)

How To Use:

Adults and elderly:

In patients with symptoms of acute inflammation, the content of one enema bottle (60 g rectal suspension) is administered into the intestine as a clyster once daily at bedtime.

Children and adolescents:

There is little experience and only limited documentation for an effect in children.

General instructions for use:

Salofalk enemas are used once daily at bedtime.
Treatment with Salofalk enemas must be administered regularly and consistently, because only in this way can healing be successfully achieved.
The duration of use is determined by the physician.

Method of administration:

Rectal use.

The best results are achieved if the bowel is emptied before administration of the Salofalk enema.

Preparation:

The correct position for administration is as follows:

The patient should lie down on his/her left side with his/her left leg stretched out and right leg bent.
This makes it easier for the rectal suspension to be administered and for the enema to be effective.

Administration of the rectal suspension:

The tip of the applicator should be inserted deep into the rectum.
The bottle should be tipped downwards slightly and then squeezed slowly.
Once the bottle is empty, the applicator tip should be slowly withdrawn from the rectum.
The patient should remain lying down in this position for at least 30 minutes to allow the contents of the enema to spread throughout the rectum.
If possible, the rectal suspension should be allowed to exert its effects all night.

Warnings And precautions:

Blood tests (differential blood count; liver function parameters like ALT or AST; serum creatinine) and urinary status (dip sticks) should be determined prior to and during treatment, at the discretion of the treating physician.
As a guideline, follow-up tests are recommended 14 days after commencement of treatment, then a further two to three tests at intervals of 4 weeks.
If the findings are normal, follow-up tests should be carried out every 3 months.
If additional symptoms occur, these tests should be performed immediately.

Caution is recommended in patients with impaired hepatic function.

Salofalk enemas should not be used in patients with impaired renal function.
Mesalazine-induced renal toxicity should be considered, if renal function deteriorates during treatment.
Patients with pulmonary disease, in particular asthma, should be very carefully monitored during a course of treatment with Salofalk enemas.
Patients with a history of adverse drug reactions to preparations containing sulphasalazine should be kept under close medical surveillance on commencement of a course of treatment with Salofalk enemas.
Should Salofalk enemas cause acute intolerance reactions such as abdominal cramps, acute abdominal pain, fever, severe headache and rash, therapy should be discontinued immediately.
Due to their potassium metabisulphite content, Salofalk enemas can provoke allergic reactions with anaphylactic symptoms and bronchial constriction (bronchospasm) in sensitive patients, particularly in those with asthma or a history of allergies.
Because the product contains sodium benzoate, it may provoke hypersensitivity reactions in suitably predisposed patients in the form of irritation of the skin, eyes and mucous membranes.

Ingredients:

Salofalk Enemas 4mg / 60ml - 7 pcs